GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Anthem Biosciences Ltd

Anthem Biosciences Q2 FY27 Standalone Profit Rises to ₹2,208.86 Million

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 03 Nov 2026, 05:54 PM IST  ·  BSE ID: 9d50d3df-2a65-4fc2-b2cd-f4cef827cc8f
View Original BSE Filing (PDF)
💡
In Simple Terms
Anthem Biosciences reported higher standalone profit of ₹2,208.86 Million for the quarter ending September 2026.
🤖 AI Summary
  • Anthem Biosciences Ltd's standalone profit for Q2 FY27 increased to ₹2,208.86 Million from ₹1,984.34 Million in Q2 FY26.
  • Revenue from operations for the quarter ended September 30, 2026, stood at ₹5,721.08 Million.
  • For the half year ended September 30, 2026, standalone profit was ₹3,228.95 Million.
  • Total equity as of September 30, 2026, was reported at ₹34,147.83 Million.
  • The Board of Directors approved Unaudited Standalone and Consolidated Financial Results for the period.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
₹5,721.08 Million
3.51
Profit for the period (Q2 FY27)
₹2,208.86 Million
11.31
Revenue from operations (H1 FY27)
₹9,559.50 Million
-12.38
Profit for the period (H1 FY27)
₹3,228.95 Million
-6.89
Total Assets (September 30, 2026)
₹37,842.79 Million
🏢 How This Affects the Company
📈
Business Impact
Revenue from operations for Q2 FY27 increased to ₹5,721.08 Million compared to ₹5,527.03 Million in Q2 FY26, indicating growth in core business activities.
💰
Financial Impact
Standalone profit for Q2 FY27 rose to ₹2,208.86 Million, reflecting improved profitability compared to the prior year's comparable quarter. Total assets increased to ₹37,842.79 Million as of September 30, 2026.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, with Q2 FY27 standalone profit increasing to ₹2,208.86 Million and half-year profit reported at ₹3,228.95 Million.
🔍
Management Signal
The Board's approval of the unaudited financial results signals routine financial reporting and compliance with SEBI regulations.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check for sustained revenue growth and profitability.
Future investor calls or presentations — monitor management commentary on H1 performance.
Analysis of Consolidated Financial Results — assess overall group performance.
MEDIUM RISK While quarterly profit improved, the half-year revenue decline suggests potential challenges in the operating environment.
💡 Investor Takeaway
Anthem Biosciences Ltd reported Unaudited Standalone Financial Results for Q2 FY27. Profit for the period rose 11.31% to ₹2,208.86 Million from ₹1,984.34 Million in Q2 FY26. Revenue from operations increased to ₹5,721.08 Million. Half-year revenue from operations declined 12.38% to ₹9,559.50 Million.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Profit for Q2 FY27 increased by 11.31% to ₹2,208.86 Million from ₹1,984.34 Million in Q2 FY26.
  • Revenue from operations grew by 3.51% to ₹5,721.08 Million in Q2 FY27 compared to ₹5,527.03 Million in Q2 FY26.

⚠️ Concerns

  • Half-year revenue from operations declined by 12.38% to ₹9,559.50 Million for H1 FY27 from ₹10,913.71 Million in H1 FY26.
  • Net cash used in investing activities for H1 FY27 was ₹(1,890.80) Million, an increase from ₹(1,857.19) Million in H1 FY26.
📅 Company Track Record
Anthem Biosciences previously reported Q2 FY27 PAT up 21.9% to ₹2,115 Mn in a press release dated November 03, 2026, and Q1 FY27 net profit decreased 11.7% YoY to ₹1,199 Mn in a revised press release dated July 21, 2026. This filing details the standalone results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Anthem Biosciences' standalone net profit for Q2 FY27?
Anthem Biosciences' standalone profit for the quarter ended September 30, 2026 (Q2 FY27) was ₹2,208.86 Million, an increase from ₹1,984.34 Million in Q2 FY26.
What was Anthem Biosciences' revenue from operations in Q2 FY27?
Revenue from operations for Anthem Biosciences in Q2 FY27 was ₹5,721.08 Million, compared to ₹5,527.03 Million in the same quarter last year.
What is Anthem Biosciences' half-year standalone profit for H1 FY27?
For the half year ended September 30, 2026 (H1 FY27), Anthem Biosciences reported a standalone profit of ₹3,228.95 Million, a decrease from ₹3,467.73 Million in H1 FY26.
What were the total expenses for Anthem Biosciences in Q2 FY27?
Total expenses for Anthem Biosciences in Q2 FY27 were ₹3,326.86 Million, down from ₹3,527.23 Million in Q2 FY26.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.